Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is considered the predominant cause of dementia worldwide. Pathologically, the disease has been attributed to excessive accumulation of amyloid-β peptide and hyperphosphorylated tau protein leading to the formation of amyloid plaques and tau tangles, respectively. Currently, management of AD is extensively based on cholinesterase inhibitors, such as donepezil (DPZ), which provide symptomatic improvement. While there is no disease-modifying treatment, our lab has shown that tolfenamic acid (TA), a non-steroidal anti-inflammatory drug (NSAID), has potential disease-modifying properties independent of its anti-inflammatory effects. Thus, here we intended to compare it with DPZ, the most commonly prescribed treatment for AD, on behavior and tau pathology biomarker levels using an hTau transgenic mouse model and an in vitro model. A prototypical NSAID, ibuprofen (IBP), was used to further confirm that TA’s effects are independent of its anti-inflammatory properties. Our findings show that total tau and its hyperphosphorylation levels were reduced in TA and DPZ treated mice, and IBP had no such effects on these markers. Treatments that reduced tau levels provided consistent improvement of cognitive performance as measured by the Morris Water Maze (MWM). Further we demonstrated TA effects on neuroblastoma cell line in which both TA and DPZ reduced total tau protein level, but not ibuprofen.
|Advisor:||Zawia, Nasser H.|
|Commitee:||Quinlan, Katharina A., Weyandt, Lisa L.|
|School:||University of Rhode Island|
|School Location:||United States -- Rhode Island|
|Source:||MAI 81/6(E), Masters Abstracts International|
|Keywords:||Alzheimer’s disease, Cognitive performance, Comparative study, Donepezil, Tau pathology, Tolfenamic acid|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be